Miravirsen: Phase II started

Santaris began an open-label, U.S. Phase II trial evaluating two dosing regimens of subcutaneous miravirsen in combination with telaprevir and ribavirin in 20 patients with HCV genotype 1 infection who are null responders to pegylated interferon alpha and ribavirin. Patients will receive 5 doses of once-weekly 7 mg/kg miravirsen followed by either 6 doses of 5 mg/kg miravirsen given once every other week or 3 doses of monthly 7 mg/kg miravirsen. ...